E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

This study tests a specialized immune cell therapy (called E7 TCR-T cell therapy) for people with cancers caused by a specific strain of the human papillomavirus (HPV-16), including cervical, head and neck, anal, and other HPV-related cancers that have spread or returned after standard treatment. **You may be eligible if...** - You are 18 or older - You have a confirmed HPV-16 positive cancer that has spread or is recurring - Your tumor has been confirmed to carry the HPV-16 strain - You carry a specific immune system marker called HLA-A*02:01 - Your cancer has measurable disease on scans - You have received or declined standard first-line treatment - You are in good physical health (ECOG 0–1) **You may NOT be eligible if...** - Your tumor does not carry HPV-16 - You do not have the HLA-A*02:01 genetic marker - You have more than 3 brain metastases, or brain metastases that are not stable - You are pregnant or unwilling to use contraception - You have serious autoimmune disease or are on immunosuppressive medications Talk to your doctor to see if this trial is right for you.